About

About Phagenesis Phagenesis is a leading medical technology company pioneering neuromodulation therapy for neurogenic dysphagia, a swallowing disorder commonly seen after stroke or other neurological injury. The company’s Phagenyx® Neuromodulation System delivers pharyngeal electrical stimulation (PES) to retrain neural pathways and restore swallowing control. Supported by more than 30 clinical publications and real-world evidence, Phagenyx has demonstrated faster return to oral nutrition, reduced aspiration risk and shorter hospital stays. In the United States, Phagenyx is indicated for treating severe dysphagia post-stroke, while outside the U.S., it is CE-marked for use in a broad range of neurological causes.